Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517837 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants
A Early Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
NCT05517837: Clinical Trial Early Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT05517837 is a Early Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05517837, a Early Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986421 in healthy adult participants.
Interventions
- OTHER Placebo
- DRUG BMS-986421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-07-14 |
| Phase | Early Phase 1 |
Why NCT05517837 stopped before completion
NCT05517837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05517837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05517837 about?
NCT05517837 is a clinical study titled "A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of BMS-986421 in healthy adult participants.
What is the current status of trial NCT05517837?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2022-09-13. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05517837?
The interventions under investigation include: Placebo (OTHER), BMS-986421 (DRUG).
Who is sponsoring clinical trial NCT05517837?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05517837's enrollment target sits among peer trials
46 566th of 2000 higher than 1,426 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI